Since last summer, the FDA has been recalling blood pressure medications known as angiotensin II receptor blockers (ARBs) that contain the ingredients irbesartan, losartan, or valsartan for potentially posing a cancer risk. Many of these recalled medications have been contaminated in the manufacturing process, particularly from Chinese facilities. In 2016, these drugs have been dispensed to over 60 million users. As the investigation continues, the FDA plans to strengthen their control over manufacturing practices. For more on the case, click here.